Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 6:3:141.
doi: 10.3389/fonc.2013.00141. eCollection 2013.

Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group

Neerav Shukla  1 , Joshua Schiffman, Damon Reed, Ian J Davis, Richard B Womer, Stephen L Lessnick, Elizabeth R Lawlor; COG Ewing Sarcoma Biology Committee
Affiliations

Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group

Neerav Shukla et al. Front Oncol. .

Abstract

A goal of the COG Ewing Sarcoma (ES) Biology Committee is enabling identification of reliable biomarkers that can predict treatment response and outcome through the use of prospectively collected tissues and correlative studies in concert with COG therapeutic studies. In this report, we aim to provide a concise review of the most well-characterized prognostic biomarkers in ES, and to provide recommendations concerning design and implementation of future biomarker studies. Of particular interest and potentially high clinical relevance are studies of cell-cycle proteins, sub-clinical disease, and copy number alterations. We discuss findings of particular interest from recent biomarker studies and examine factors important to the success of identifying and validating clinically relevant biomarkers in ES. A number of promising biomarkers have demonstrated prognostic significance in numerous retrospective studies and now need to be validated prospectively in larger cohorts of equivalently treated patients. The eventual goal of refining the discovery and use of clinically relevant biomarkers is the development of patient specific ES therapeutic modalities.

Keywords: Ewing sarcoma; biomarkers; predictive; prognostic.

PubMed Disclaimer

References

    1. Abudu A., Mangham D. C., Reynolds G. M., Pynsent P. B., Tillman R. M., Carter S. R., et al. (1999). Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis. Br. J. Cancer 79, 1185–118910.1038/sj.bjc.6690190 - DOI - PMC - PubMed
    1. Altman D. G., Mcshane L. M., Sauerbrei W., Taube S. E. (2012). Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 10:51.10.1186/1741-7015-10-51 - DOI - PMC - PubMed
    1. Armengol G., Tarkkanen M., Virolainen M., Forus A., Valle J., Bohling T., et al. (1997). Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br. J. Cancer 75, 1403–140910.1038/bjc.1997.242 - DOI - PMC - PubMed
    1. Ash S., Luria D., Cohen I. J., Goshen Y., Toledano H., Issakov J., et al. (2011). Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin. Cancer Res. 17, 2900–290710.1158/1078-0432.CCR-10-3069 - DOI - PubMed
    1. Asmane I., Watkin E., Alberti L., Duc A., Marec-Berard P., Ray-Coquard I., et al. (2012). Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur. J. Cancer 48, 3027–303510.1016/j.ejca.2012.05.009 - DOI - PubMed

LinkOut - more resources